DMI 9523

Drug Profile

DMI 9523

Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523; LMWF 5A

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Antirheumatics; Dipeptides; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Immunomodulators; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase I Crohn's disease
  • Preclinical Chronic obstructive pulmonary disease
  • Research Eye disorders
  • No development reported Inflammation; Neurological disorders; Rhinitis

Most Recent Events

  • 18 Sep 2017 Ampio Pharmaceuticals completes enrolment in a phase III trial in Osteoarthritis in USA
  • 08 Aug 2017 Ampio Pharmaceuticals receives patent allowance for DMI-9523 in USA
  • 06 Jun 2017 Ampio Pharmaceuticals announces intention to submit BLA to US FDA for Osteoarthritis by end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top